Androgen deprivation therapy (ADT) has long been the standard-of-care treatment for patients with advanced prostate cancer (PC) [1] and is often utilized in patients with biochemically recurrent (BCR) PC with rising prostate-specific antigen (PSA) after completion of definitive/or and salvage local therapy. This evidence concerns the gene KLK3 and prostate cancer.